Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

Amer M. Zeidan; Ju Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R. Smith; Elisabeth Paietta; Janice Gabrilove; Harry P. Erba; Martin S. Tallman; Steven D. Gore

doi:10.1111/bjh.12884

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

Amer M. Zeidan, Ju Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R. Smith, Elisabeth Paietta, Janice Gabrilove, Harry P. Erba, Martin S. Tallman, Steven D. Gore

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Summary: The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.

Original language	English (US)
Pages (from-to)	352-359
Number of pages	8
Journal	British journal of haematology
Volume	166
Issue number	3
DOIs	https://doi.org/10.1111/bjh.12884
State	Published - Aug 2014
Externally published	Yes

Keywords

Azacitidine
French Prognostic Scoring System
Myelodysplastic syndromes
Prognostic models
Revised International Prognostic Scoring System

Access

10.1111/bjh.12884

OpenUrl availability

Full text

Cite this

Zeidan, A. M., Lee, J. W., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., Smith, M. R., Paietta, E., Gabrilove, J., Erba, H. P., Tallman, M. S., & Gore, S. D. (2014). Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. British journal of haematology, 166(3), 352-359. https://doi.org/10.1111/bjh.12884

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. / Zeidan, Amer M.; Lee, Ju Whei; Prebet, Thomas et al.
In: British journal of haematology, Vol. 166, No. 3, 08.2014, p. 352-359.

Research output: Contribution to journal › Article › peer-review

Zeidan, AM, Lee, JW, Prebet, T, Greenberg, P, Sun, Z, Juckett, M, Smith, MR, Paietta, E, Gabrilove, J, Erba, HP, Tallman, MS & Gore, SD 2014, 'Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes', British journal of haematology, vol. 166, no. 3, pp. 352-359. https://doi.org/10.1111/bjh.12884

@article{360413fcc048470796ac8ca88632df29,

title = "Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes",

abstract = "Summary: The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.",

keywords = "Azacitidine, French Prognostic Scoring System, Myelodysplastic syndromes, Prognostic models, Revised International Prognostic Scoring System",

author = "Zeidan, {Amer M.} and Lee, {Ju Whei} and Thomas Prebet and Peter Greenberg and Zhuoxin Sun and Mark Juckett and Smith, {Mitchell R.} and Elisabeth Paietta and Janice Gabrilove and Erba, {Harry P.} and Tallman, {Martin S.} and Gore, {Steven D.}",

year = "2014",

month = aug,

doi = "10.1111/bjh.12884",

language = "English (US)",

volume = "166",

pages = "352--359",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

AU - Zeidan, Amer M.

AU - Lee, Ju Whei

AU - Prebet, Thomas

AU - Greenberg, Peter

AU - Sun, Zhuoxin

AU - Juckett, Mark

AU - Smith, Mitchell R.

AU - Paietta, Elisabeth

AU - Gabrilove, Janice

AU - Erba, Harry P.

AU - Tallman, Martin S.

AU - Gore, Steven D.

PY - 2014/8

Y1 - 2014/8

N2 - Summary: The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.

AB - Summary: The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.

KW - Azacitidine

KW - French Prognostic Scoring System

KW - Myelodysplastic syndromes

KW - Prognostic models

KW - Revised International Prognostic Scoring System

UR - http://www.scopus.com/inward/record.url?scp=84904042149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904042149&partnerID=8YFLogxK

U2 - 10.1111/bjh.12884

DO - 10.1111/bjh.12884

M3 - Article

C2 - 24712482

AN - SCOPUS:84904042149

SN - 0007-1048

VL - 166

SP - 352

EP - 359

JO - British journal of haematology

JF - British journal of haematology

IS - 3

ER -

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes

Abstract

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this